DNA Origami Vaccine Platform Emerges as Potent Alternative to mRNA, Promising Enhanced Stability and Global Accessibility for Future Pandemic Response

The COVID-19 pandemic irrevocably propelled messenger RNA (mRNA) vaccines into the global spotlight, marking a paradigm shift in modern vaccinology. Following an unprecedented accelerated development and rigorous clinical trial phase, the world witnessed the administration of the first COVID-19 mRNA vaccine on December 8, 2020. This landmark achievement initiated a global vaccination campaign that, according to conservative estimates derived from sophisticated epidemiological modeling, prevented at least 14.4 million deaths worldwide during its crucial first year alone. This figure, published in The Lancet Infectious Diseases in June 2022, underscored the profound, life-saving impact of this nascent technology and ignited widespread optimism for its application across a spectrum of other infectious diseases.

Driven by this demonstrated efficacy and the urgent need for robust immunological tools, scientific efforts rapidly pivoted towards leveraging mRNA technology for a broader array of pathogens. Extensive ongoing clinical trials are currently targeting a diverse range of infectious agents, including the highly prevalent influenza virus, Respiratory Syncytial Virus (RSV), the Human Immunodeficiency Virus (HIV), Zika virus, Epstein-Barr virus, and even the tuberculosis bacteria. The ambition is clear: to replicate the success seen with SARS-CoV-2 and provide potent, rapidly deployable defenses against persistent and emerging global health threats. However, amidst this fervent development, detailed studies of the COVID-19 mRNA vaccines have also illuminated critical limitations, highlighting the imperative for novel, complementary, and potentially superior vaccine strategies to fully address the complexities of infectious disease prevention.

The Double-Edged Sword of mRNA Vaccines: Performance and Production Challenges

While revolutionary, the performance and logistical profiles of COVID-19 mRNA vaccines have presented significant hurdles. A primary concern revolves around the variability and durability of immune protection. The level of immune response generated by these vaccines can differ widely among individuals, influenced by factors such as age, underlying health conditions, and genetic predisposition. Crucially, the protective immunity conferred by mRNA vaccines does not last indefinitely. This waning immunity necessitates booster shots and poses a continuous challenge in maintaining population-level protection.

This issue is further exacerbated by the relentless evolutionary pressure on pathogens like SARS-CoV-2. The virus’s capacity for rapid mutation leads to the emergence of new variants (such as Alpha, Delta, Omicron, and their numerous sub-lineages) that can partially evade existing immune defenses, a phenomenon known as antigenic escape. This constant antigenic drift means that vaccine formulations often require frequent updates to remain effective, mirroring the annual reformulation of influenza vaccines. Such updates entail significant research and development cycles, regulatory approvals, and manufacturing adjustments, adding layers of complexity to pandemic preparedness.

Beyond immunological considerations, mRNA vaccines grapple with substantial practical and logistical challenges. Manufacturing these vaccines is an inherently complex and expensive endeavor. The process involves synthesizing high-quality mRNA, which is then encapsulated within lipid nanoparticles (LNPs). Controlling the precise number of mRNA molecules packaged into these LNPs – a critical factor for vaccine efficacy and safety – remains a technically difficult and resource-intensive task. Furthermore, the inherent instability of mRNA molecules necessitates stringent cold chain requirements. For instance, Pfizer-BioNTech’s mRNA vaccine initially required ultra-cold storage at -70°C, while Moderna’s required -20°C. Although formulations have improved to allow for more standard refrigeration for shorter periods, these requirements are still considerably more demanding than those for traditional protein-based or inactivated vaccines, posing immense challenges for global distribution, particularly in regions with limited infrastructure and unreliable power grids. There is also the potential for unintended off-target effects, though rare, such as myocarditis and pericarditis observed in some younger individuals after mRNA vaccination, underscoring the need for platforms with precise control over immune activation. Overcoming these multifaceted limitations is paramount to enhancing global preparedness and optimizing responses to future infectious disease threats.

DoriVac: A DNA Origami Vaccine Platform Offering a Transformative Alternative

In response to these pressing challenges, a pioneering multidisciplinary team comprising researchers from the Wyss Institute at Harvard University, Dana-Farber Cancer Institute (DFCI), and their partner institutions has embarked on an innovative journey to explore a fundamentally different approach. Their work has led to the development of a novel DNA origami nanotechnology platform dubbed DoriVac, which functions not only as a vaccine antigen delivery system but also intrinsically as an immune-stimulating adjuvant.

DNA origami is a revolutionary field of nanotechnology where DNA strands are meticulously folded and self-assembled into precise, custom-designed two-dimensional and three-dimensional nanostructures. This precise programmability allows for the spatial arrangement of molecules at the nanoscale with unprecedented control. The researchers ingeniously designed DoriVac vaccines to target a conserved peptide region known as HR2, which is present in the spike proteins of several formidable viruses, including SARS-CoV-2, HIV, and Ebola. Focusing on conserved regions is a strategic move, as these areas are less prone to mutation, potentially offering broader and more durable protection against viral variants.

Initial preclinical testing in mouse models yielded highly encouraging results. The SARS-CoV-2 HR2 vaccine formulated using the DoriVac platform triggered robust and broad immune responses, encompassing both antibody-driven (humoral) and T cell-driven (cellular) activity. Humoral immunity, mediated by antibodies, is crucial for neutralizing free virus particles, while cellular immunity, driven by T cells, is vital for identifying and eliminating infected cells, providing a more comprehensive defense.

To further validate these findings and bridge the critical gap between animal models and human physiology, the team leveraged the Wyss Institute’s advanced microfluidic human Organ Chip technology. This sophisticated in vitro system simulates the complex microenvironment and functionality of a human lymph node, providing a more accurate predictive model for human immune responses. In this cutting-edge system, the SARS-CoV-2 HR2 DoriVac vaccine also generated strong antigen-specific immune responses in human cells, lending significant credibility to its potential for human application.

Crucially, when directly compared with conventional SARS-CoV-2 mRNA vaccines delivered through lipid nanoparticles, a DoriVac vaccine carrying the identical spike protein variant produced a similarly strong immune activation in these sophisticated human models. However, the DNA origami vaccine showcased distinct and significant advantages in terms of stability, and demonstrated greater ease of storage and manufacturing. These groundbreaking findings were meticulously documented and subsequently reported in the prestigious scientific journal Nature Biomedical Engineering.

Dr. William Shih, a co-corresponding author and Wyss Institute Core Faculty member, whose group pioneered this novel vaccine concept, articulated the platform’s transformative potential: "With the DoriVac platform, we have developed an extremely flexible chassis with a number of critical advantages, including an unprecedented control over vaccine composition, and the ability to program immune recognition in targeted immune cells on a molecular level to achieve better responses." Dr. Shih, who also holds a professorship at Harvard Medical School and DFCI, emphasized, "Our study demonstrates DoriVac’s versatility and potential by taking a close look at the immune changes that are required to fight infectious viruses."

The Engineering Marvel: How DNA Origami Vaccines Are Constructed

The conceptualization and initial development of DoriVac as a DNA nanotechnology-based vaccine platform with broad potential applications were formally introduced by Dr. Shih’s team at the Wyss Institute and Dana-Farber in 2024. Dr. Yang (Claire) Zeng, M.D., Ph.D., who spearheaded the collaborative effort, was instrumental in demonstrating DoriVac’s ability to precisely present immune-stimulating adjuvant molecules to cells at the nanoscale. This precise spatial arrangement is a hallmark of DNA origami, allowing for optimized engagement with immune cells.

Earlier investigations focusing on cancer applications in tumor-bearing mice had already revealed DoriVac’s superior immune-stimulating capabilities, producing significantly stronger immune responses than vaccine versions lacking the intricate DNA origami structure. DoriVac vaccines are ingeniously constructed from tiny, self-assembling square DNA nanostructures. One side of this nanostructure is engineered to display adjuvant molecules, arranged at carefully controlled nanometer distances, which are critical for activating immune cells. The opposite side is designed to present selected antigens, such as peptides or proteins derived from tumors or, in this case, pathogens.

Dr. Zeng, who serves as a first and co-corresponding author on the new study and is now cofounder and CEO/CTO of DoriNano, leading the translation of this technology into clinical applications, recounted the pivot to infectious diseases: "While we were developing the platform for cancer applications, the COVID-19 pandemic was still moving with full force. So, the question quickly arose whether DoriVac’s superior adjuvant activity could also be leveraged in infectious disease settings." This adaptability underscores the platform’s inherent versatility.

To thoroughly explore this promising avenue, Dr. Zeng and co-first author Dr. Olivia Young, a former graduate student in Dr. Shih’s group, initiated a crucial collaboration with Dr. Donald Ingber’s team at the Wyss Institute. Dr. Ingber’s group is renowned for its innovative work in antiviral innovation, utilizing advanced AI-driven and multiomics approaches in conjunction with sophisticated microfluidic human Organ Chip systems. Working synergistically with co-first author Dr. Longlong Si, a former postdoctoral researcher in Dr. Ingber’s lab, the researchers successfully developed DoriVac vaccines specifically targeting SARS-CoV-2, HIV, and Ebola. These vaccines strategically present the HR2 peptides, which, as conserved antigens within the respective viral spike proteins, offer the potential for broad-spectrum protection against evolving viral strains.

Commenting on the initial findings, Dr. Zeng stated, "Our analysis of the immune responses provoked by these first DoriVac vaccines in mice led to several encouraging observations, including significantly greater and broader activation of humoral and cellular immunity across a range of relevant immune cell types than what the origami-free antigens and adjuvants could produce." She further elaborated, "We found that the numbers of antibody-producing B cells, activated antigen-presenting dendritic cells (DCs), and antigen-specific memory and cytotoxic T cell types that are vital for long-term protection were all increased, especially in the case of the SARS-CoV-2 HR2." This comprehensive activation of multiple arms of the immune system points to a robust and potentially long-lasting protective response.

Bridging the Translational Gap: From Mouse Studies to Advanced Human Models

A persistent and formidable challenge in vaccine development is the often-discrepant nature of immune responses observed in animal models, particularly mice, compared to those in humans. This translational gap has historically led to the failure of numerous promising treatments during costly and time-consuming clinical trials. To overcome this critical hurdle and enhance the predictability of human outcomes, the research team strategically employed the Wyss Institute’s advanced human lymph node-on-a-chip (human LN Chip) technology to test the DoriVac vaccines. This sophisticated in vitro system meticulously mimics key aspects of the human immune system, including cellular composition, architecture, and immunological function.

This innovative system, further advanced by co-first author Min Wen Ku and co-corresponding author Dr. Girija Goyal, Director of Bioinspired Therapeutics at the Wyss Institute, proved instrumental in validating DoriVac’s human potential. The human LN Chip experiments demonstrated that the SARS-CoV-2-HR2 DoriVac vaccine effectively activated human dendritic cells (DCs) – crucial antigen-presenting cells that initiate immune responses – and significantly increased their production of inflammatory cytokines compared to origami-free components. Furthermore, it led to a marked increase in the number of CD4+ (helper) and CD8+ (cytotoxic) T cells, both of which possess multiple protective functions vital for controlling viral infections and establishing immunological memory. These findings provided compelling human-relevant evidence, further bolstering the platform’s promise for clinical translation.

Dr. Donald Ingber, a co-corresponding author, and a distinguished figure as the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, as well as the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences, underscored the significance of this approach: "The predictive capabilities of human LN Chips gave us an ideal testing ground for DoriVac vaccines and the induced, antigen-specific immune cell profiles and activities very likely reflect those that would occur in human recipients of the vaccines. This convergence of technologies enabled us to dramatically raise the chances of success for a new class of vaccines and create a new testbed for future vaccine developments." This statement highlights the strategic importance of human organ-on-chip technology in accelerating the development of next-generation therapies.

Head-to-Head: DoriVac Versus Established mRNA Vaccines

To robustly assess DoriVac’s competitive standing, the researchers undertook a direct comparative study. They evaluated a DoriVac vaccine that presents the full SARS-CoV-2 spike protein and compared its performance against commercially available mRNA lipid nanoparticle (LNP) vaccines from Moderna and Pfizer/BioNTech, which encode the same spike protein. This crucial head-to-head comparison was led by Dr. Zeng and co-author Qiancheng Xiong.

Utilizing a standard booster approach in mouse models, the findings were highly compelling: both vaccine types produced remarkably similar antiviral T cell and antibody-producing B cell responses. This outcome is profoundly significant, as it indicates that the DoriVac platform can elicit immune responses comparable in strength and breadth to the current gold standard mRNA vaccines, yet potentially circumventing many of their inherent limitations.

Dr. Shih further elaborated on DoriVac’s distinct advantages, stating, "This underscored DoriVac’s potential as a DNA nanotechnology-enabled, self-adjuvanted vaccine platform. But DoriVac vaccines have a number of other advantages: they don’t have the same cold-chain requirements as mRNA-LNP vaccines do and thus could be distributed much more effectively, especially in under-resourced regions; and they could overcome some of the enormous manufacturing complexities of LNP-formulated vaccines, to name two major ones." The implications for global health equity are profound, as the relaxation of stringent cold chain requirements could dramatically improve vaccine accessibility in developing nations, where ultra-cold storage is often non-existent. Furthermore, DoriNano’s recent studies have also indicated that DoriVac exhibits a promising safety profile, adding another layer of confidence to its potential clinical translation.

Broader Impact and Future Implications

The emergence of the DoriVac platform represents a significant leap forward in vaccinology, promising not only a robust alternative to current mRNA technologies but also a powerful tool for global pandemic preparedness. The unparalleled control over vaccine composition and the ability to program immune recognition at a molecular level, as highlighted by Dr. Shih, opens doors to designing highly targeted and effective vaccines against a myriad of pathogens, potentially even those for which vaccines have remained elusive, such as HIV. This modularity could enable rapid adaptation to new viral variants or entirely novel threats, streamlining the vaccine development timeline during future health crises.

From a global health perspective, the implications of DoriVac’s enhanced stability, reduced cold-chain requirements, and simplified manufacturing process are transformative. The challenges of distributing mRNA vaccines, particularly in low-income countries, were starkly evident during the initial phases of the COVID-19 vaccine rollout. DoriVac’s potential to be stored at ambient temperatures or standard refrigeration could dramatically improve logistical feasibility, reduce transportation costs, and ensure equitable access to life-saving vaccines worldwide, thereby strengthening global health security and resilience against future pandemics.

Moreover, the platform’s origins in cancer research underscore its versatility. Beyond infectious diseases, DoriVac holds immense potential for therapeutic applications in oncology, autoimmune disorders, and allergies, where precise immune modulation is critical. The collaborative excellence demonstrated by the multidisciplinary team from the Wyss Institute, Dana-Farber Cancer Institute, and their partners, alongside diverse funding from institutions like the National Institutes of Health, the Bill and Melinda Gates Foundation, and various national research foundations, exemplifies the collaborative spirit necessary to drive such groundbreaking innovations.

In conclusion, the DoriVac DNA origami vaccine platform stands at the precipice of revolutionizing how the world confronts infectious diseases. By addressing the critical limitations of current mRNA technologies while maintaining comparable efficacy, DoriVac offers a path towards more stable, accessible, and precisely engineered vaccines. Its development marks a pivotal moment, heralding an era of enhanced global health preparedness and a more equitable distribution of advanced medical countermeasures.

Other authors who contributed to this landmark study include Sylvie Bernier, Hawa Dembele, Giorgia Isinelli, Tal Gilboa, Zoe Swank, Su Hyun Seok, Anjali Rajwar, Amanda Jiang, Yunhao Zhai, LaTonya Williams, Caleb Hellman, Chris Wintersinger, Amanda Graveline, Andyna Vernet, Melinda Sanchez, Sarai Bardales, Georgia Tomaras, Ju Hee Ryu, and Ick Chan Kwon. The extensive research was made possible through crucial funding provided by the Director’s Fund and Validation Project program of the Wyss Institute; the Claudia Adams Barr Program at DFCI; the National Institutes of Health (U54 grant CA244726-01); the US-Japan CRDF global fund (grant R-202105-67765); the National Research Foundation of Korea (grants MSIT, RS-2024-00463774, RS-2023-00275456); the Intramural Research Program of the Korea Institute of Science and Technology (KIST); and the Bill and Melinda Gates Foundation (INV-002274).